Patents Assigned to Institut National de la Santé et de la Recherche Médicale
  • Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma
    Patent number: 8771691
    Abstract: The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: July 8, 2014
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Patricia Forgez, Marco Alifano
  • METHODS FOR DETERMINING THE EXPRESSION LEVEL OF A GENE OF INTEREST INCLUDING CORRECTION OF RT-QPCR DATA FOR GENOMIC DNA-DERIVED SIGNALS
    Publication number: 20140186845
    Abstract: The present invention relates to methods for determining the expression level of a gene of interest in a nucleic acid sample by RT-qPCR. More specifically, procedures for determining the impact of a gDNA contamination on the measured total signal have been developed allowing the correction of the signal originating from the above said gDNA. A further aspect of the invention refers to a mean by which the sensitivity qPCR primers toward gDNA can be determined.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 3, 2014
    Applicants: UNIVERSITE PAUL SABATIER - TOULOUSE III, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Henrik Laurell, Mikael Kubista, Jason Iacovoni
  • Non Human Animal Models for Increased Retinal Vascular Permeability
    Publication number: 20140186960
    Abstract: The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicant: Institut National De La Sante et De La Recherche Medicale (INSERM)
    Inventors: Abdoulaye Sene, Ramin Tadayoni, Jose Sahel, Alvaro Rendon
  • METHOD FOR PREDICTING THE RISK OF DEVELOPING A COLONIC NEOPLASIA
    Publication number: 20140186366
    Abstract: The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER - TOULOUSE III
    Inventors: Catherine Seva, Catherine Do, Audrey Ferrand, Julien Palasse, Marie-Bernadette Delisle
  • Methods and Compositions Comprising AMPK Activator (Metformin/Troglitazone) for the Treatment of Myotonic Dystrophy Type 1 (DM1)
    Publication number: 20140187595
    Abstract: The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator <eq.metformin or troglizazone>.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 3, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Sandrine Baghdoyan, Marc Peschanski, Delphine Laustriat, Jacqueline Gide
  • METHOD FOR PREDICTING INSULINOPENIC TYPE 2 DIABETES
    Publication number: 20140186829
    Abstract: The present invention relates to an in vitro method, for predicting a risk of onset of type 2 diabetes in a subject, which method comprises the steps of: a) measuring the concentration of bacterial 16S rDNA in a biological sample of said subject; and b) comparing said measured concentration of bacterial 16S rDNA to a threshold level; wherein a measured concentration of bacterial 16S rDNA higher than the threshold level is indicative of an increased risk of onset of type 2 diabetes in the subject, and a measured concentration of bacterial 16S rDNA lower than the threshold level is indicative of a decreased risk of onset of type 2 diabetes in the subject.
    Type: Application
    Filed: April 2, 2012
    Publication date: July 3, 2014
    Applicants: CHU De Toulouse, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Remy Burcelin, Jacques Amar, Beverly Balkau
  • SELECTIVE CULTURE MEDIUM AND METHOD FOR DETECTING CARBAPENEM-RESISTANT BACTERIA IN A TEST SAMPLE
    Publication number: 20140178922
    Abstract: The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.
    Type: Application
    Filed: July 5, 2012
    Publication date: June 26, 2014
    Applicants: UNIVERSITE PARIS SUD (PARIS 11), Institut National de la Sante et de la Recherche Medicale (INSERM), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Delphine Girlich, Laurent Poirel, Patrice Nordmann
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20140178308
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: July 27, 2012
    Publication date: June 26, 2014
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer
  • New Inhibitors of Cyclophilins and Uses Thereof
    Publication number: 20140179687
    Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 26, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michael Pawlotsky
  • Host cell kinases as targets for antiviral therapies against HCV infection
    Patent number: 8759010
    Abstract: The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: June 24, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thomas Baumert, Joachim Lupberger
  • FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction
    Publication number: 20140163021
    Abstract: Candidate compounds for use in neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease) are identified from a direct interaction between proteins FKBP52 and Tau. The method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a Tau polypeptide and a FKBP52 polypeptide, and selecting positively the candidate compound that modulates binding.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 12, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • SILYLATED BIOMOLECULE-BASED HYDROGEL FOR CULTURING CARDIOMYOCYTES AND STEM CELLS, AND USE OF THE HYDROGEL THEREOF FOR TREATING HEART FAILURE
    Publication number: 20140161775
    Abstract: The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.
    Type: Application
    Filed: June 4, 2012
    Publication date: June 12, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CHU NANTES, UNIVERSITE DE NANTES
    Inventors: Pierre Weiss, Eva Mathieu, Jérôme Guicheux, Patricia Lemarchand
  • Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
    Patent number: 8748493
    Abstract: The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a biological sample obtained from a subject.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: June 10, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Karine Clement, Michele Guerre Millo, Nadia Naour
  • RECOMBINANT VECTOR FOR PRODUCING AND SECRETING PEPTIDE OR PROTEIN OF INTEREST BY PROPIONIBACTERIA AND APPLICATIONS THEREOF
    Publication number: 20140154213
    Abstract: The present invention relates to a recombinant vector for expressing and secreting, by a propionibacterium, at least one eukaryotic peptide or protein of interest, comprising at least: under the control of at least one suitable promoter, at least one nucleic acid sequence encoding a propionibacterial signal peptide and, at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest; wherein said at least one nucleic acid sequence encoding a propionibacterial signal peptide is translationally fused to said at least one nucleic acid sequence encoding said eukaryotic peptide or protein of interest. The invention further relates to the uses of such a vector in the pharmaceutical field or for the large-scale production of peptides or proteins of interest.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 5, 2014
    Applicants: UNIVERSITE DE RENNES 1, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Gwenael JAN, Marie-Thérése DIMANCHE-BOITREL, Héléne FALENTIN, Charles HALOUZE
  • Serene protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
    Patent number: 8741286
    Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: June 3, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
  • PD-1 antibodies and PD-L1 antibodies and uses thereof
    Patent number: 8741295
    Abstract: The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: June 3, 2014
    Assignees: Universite de la Mediterranee, Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventor: Daniel Olive
  • Promyelocytic leukemia protein as a redox sensor
    Patent number: 8735171
    Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 27, 2014
    Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Hugues De The, Valerie Lallemand-Breitenbach
  • LINEAR DNA AMPLIFICATION
    Publication number: 20140141442
    Abstract: The present invention provides materials and methods for DNA amplification, in particular linear amplification methods using RNA polymerase. These methods permit high-throughput sequencing of pictogram amounts of DNA and are of use in a range of applications including genome-wide profiling of transcription factors and epigenetic DNA and histone modifications, global transcript profiling, mapping of chromatin conformations, as well as for forensic use and archaeological studies.
    Type: Application
    Filed: May 4, 2012
    Publication date: May 22, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
    Inventors: Luisa Miguel Verdelho Trindade Van Gerven, Hinrich Gronemeyer, Shankara Narayanan Pattabhiraman
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCERS
    Publication number: 20140142168
    Abstract: The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 22, 2014
    Applicants: CENTRE JEAN PERRIN, Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE D'AUVERGNE CLERMONT
    Inventors: Chantal Barthomeuf, Philippe Chollet, Eloise Planchat, Hervé Cure
  • POLYPEPTIDES ISOLATED FROM BREVIBACTERIUM AURANTIACUM AND THEIR USE FOR THE TREATMENT OF CANCER
    Publication number: 20140140978
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 22, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE PARIS SUD-PARIS XI, INRA (Institut National de la Recherche Agronomique)
    Inventors: David Machover, Pascal Bonnarme